Hybrid light chain mice

Patent metadata

Field	Value
Publication number	US-9035128-B2
Application number	US-201113166200-A
Country	US
Kind code	B2
Filing date	Jun 22, 2011
Priority date	Jun 22, 2010
Publication date	May 19, 2015
Grant date	May 19, 2015

Abstract

Genetically modified mice are provided that express human λ variable (hVλ) sequences, including mice that express hVλ sequences from an endogenous mouse λ light chain locus, mice that express hVλ sequences from an endogenous mouse κ light chain locus, and mice that express hVλ sequences from a transgene or an episome wherein the hVλ sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human λ variable sequences useful for making antigen-binding proteins. Compositions and methods for making antigen-binding proteins that comprise human λ variable sequences, including human antibodies, are provided.

First claim

We claim:

1. A mouse comprising at an endogenous κ light chain locus in its germline:
(a) an unrearranged light chain variable region comprising a plurality of contiguous unrearranged functional human λ light chain V (hVλ) gene segments and a plurality of contiguous unrearranged functional human λ light chain J (hJ λ) gene segments, wherein the plurality of hV λ gene segments and the plurality of hJ λ gene segments are the only functional variable region gene segments in the unrearranged light chain variable region; and
(b) a mouse κ light chain constant region gene,

wherein the plurality of contiguous unrearranged functional human λ light chain V (hVλ) gene segments and the plurality of contiguous unrearranged functional human λ light chain J (hJ λ) gene segments are operably linked to the mouse κ light chain constant region gene such that the unrearranged light chain variable region is capable of rearranging to form a rearranged human λ light chain variable region and the mouse expresses antibodies comprising a light chain comprising a variable region encoded by the rearranged human λ light chain variable region and a constant region encoded by the mouse κ light chain constant region gene.

2. The mouse of claim 1 , wherein the plurality of unrearranged hVλ gene segments are at least 12 hVλ gene segments.

3. The mouse of claim 1 , wherein the plurality of hJλ gene segments are selected from the group consisting of Jλ1, Jλ2, Jλ3, Jλ7, and a combination thereof.

4. The mouse of claim 1 , wherein an endogenous mouse X light chain locus is deleted in whole or in part.

5. The mouse of claim 1 , wherein about 10% to about 45% of the B cells of the mouse express the antibodies comprising a light chain comprising a variable region encoded by the rearranged human λ light chain variable region and a constant region encoded by the mouse κ light chain constant region gene.

6. The mouse of claim 5 , wherein the light chain variable region of the antibody is derived from a rearranged hVλ/hJλ sequence selected from the group consisting of 3-1/1, 3-1/7, 4-3/1, 4-3/7, 2-8/1, 3-9/1, 3-10/1, 3-10/3, 3-10/7, 2-14/1, 3-19/1, 2-23/1, 3-25/1, 1-40/1, 1-40/2, 1-40/3, 1-40/7, 7-43/1, 7-43/3, 1-44/1, 1-44/7, 5-45/1, 5-45/2, 5-45/7, 7-46/1, 7-46/2, 7-46/7, 9-49/1, 9-49/2, 9-49/7 and 1-51/1.

7. The mouse of claim 1 , wherein the unrearranged light chain variable region comprises a human Vκ-Jκ intergenic region from a human κ light chain locus located downstream of the most 3′ hVλ gene segment and upstream of the most 5′ hJλ gene segment.

8. A mouse comprising at an endogenous κ light chain locus in its germline:
(a) an unrearranged light chain variable region comprising:
(i) at least 12 contiguous unrearranged functional human λ light chain variable region (hVλ) gene segments and a plurality of contiguous unrearranged functional human λ light chain J (hJλ) gene segments, wherein the at least 12 functional hVλ gene segments and the plurality of functional hJλ gene segments are the only functional variable region gene segments in the unrearranged light chain variable region; and
(ii) a human Vκ-Jκ intergenic sequence located between the contiguous hVλ gene segments and the plurality of contiguous hJλ gene segments; and

(b) a mouse κ light chain constant region gene;

wherein the at least 12 contiguous unrearranged functional human λ light chain V (hVλ) gene segments and the plurality of contiguous unrearranged functional human λ light chain J (hJ λ) gene segments are operably linked to the mouse κ light chain constant region gene such that the unrearranged light chain variable region is capable of rearranging to form a rearranged human λ light chain variable region and the mouse expresses antibodies comprising a light chain comprising a variable region encoded by the rearranged human λ light chain variable region and a constant region encoded by the mouse κ light chain constant region gene.

9. The mouse of claim 8 , wherein the unrearranged light chain variable region comprises at least 28 unrearranged hVλ gene segments.

10. The mouse of claim 8 , wherein the unrearranged light chain variable region comprises at least 40 unrearranged hVλ gene segments.

11. The mouse of claim 7 , wherein the human Vκ-Jκ intergenic region comprises SEQ ID NO: 100.

12. An isolated cell of the mouse of claim 1 .

13. The cell of claim 12 , wherein the cell is a B cell.

14. An isolated cell of the mouse of claim 8 .

15. The cell of claim 14 , wherein the cell is a B cell.

16. The mouse of claim 1 , wherein the plurality of hJλ gene segments comprises 4 hJλ gene segments.

17. The mouse of claim 16 , wherein the 4 hJλ gene segments are Jλ1, Jλ2, Jλ3 and Jλ7.

18. The mouse of claim 8 , wherein the plurality of hJλ gene segments comprises 4 hJλ gene segments.

19. The mouse of claim 18 , wherein the 4 hJλ gene segments are Jλ1, Jλ2, Jλ3 and Jλ7.

Assignees

• Macdonald Lynn
• Stevens Sean
• Gurer Cagan
• Murphy Andrew J
• Hosiawa Karolina A
• Regeneron Pharma

Inventors

• Macdonald Lynn
• Stevens Sean
• Gurer Cagan
• Murphy Andrew J
• Hosiawa Karolina A

Classifications

• A01K67/0275 Primary

  Genetically modified vertebrates, e.g. transgenic · CPC title

• C12N2015/8518

  expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles · CPC title

• C07K16/18

  against material from animals or humans · CPC title

• A01K2267/01

  Animal expressing industrially exogenous proteins · CPC title

• A01K2227/105

  Murine · CPC title